Stockscreener 앱 받기
4.33
0.23%
0.010
시간 외 거래:
4.33
전일 마감가:
$4.32
열려 있는:
$4.34
하루 거래량:
44,756
Relative Volume:
0.19
시가총액:
$155.23M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.10%
1개월 성능:
-1.37%
6개월 성능:
-0.92%
1년 성능:
+0.00%
1일 변동 폭
$4.2702
$4.35
1주일 범위
$4.12
$4.49
52주 변동 폭
$2.88
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
명칭
Bioage Labs Inc
전화
510-806-1445
주소
5885 HOLLIS STREET, EMERYVILLE
BIOA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
4.33 | 155.23M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2024-12-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-21 | 개시 | Citigroup | Buy |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-21 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
Smart tools for monitoring BioAge Labs Inc.’s price actionAI-Powered Stock Trend Movement Analysis - Newser
What makes BioAge Labs Inc. stock price move sharplyFree Growth Focused Entry Plan Suggestions - Newser
Cautious Outlook on BioAge Labs, Inc. Amid Uncertainties in Clinical Developments and Market Perception - TipRanks
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M - The Motley Fool
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M - Nasdaq
BioAge Labs, Inc. Advances Clinical Pipeline with BGE-102 Phase 1 Trial Set for 2H 2025 and Expands APJ Agonist Pipeline - Quiver Quantitative
BioAge Labs Q2 2025: BGE-102 on track for Phase 1, expanded APJ pipeline, strengthened discovery platform. - AInvest
BioAge Labs Pipeline Expands: Key NLRP3 Drug Enters Clinical Phase, Secures 4-Year Cash Runway - Stock Titan
Full technical analysis of BioAge Labs Inc. stockFree Fundamental Growth Stock Analysis - Newser
What are the technical indicators suggesting about BioAge Labs Inc.Maximize your returns with expert insights - Jammu Links News
What catalysts could drive BioAge Labs Inc. stock higher in 2025Dynamic investment growth - Jammu Links News
What is BioAge Labs Inc. company’s growth strategyHigh-margin investment plays - Jammu Links News
How does BioAge Labs Inc. compare to its industry peersDiscover undervalued stocks before they soar - Jammu Links News
Is BioAge Labs Inc. a growth stock or a value stockSkyrocketing returns - Jammu Links News
Should I hold or sell BioAge Labs Inc. stock in 2025Rapid market gains - Jammu Links News
What are the latest earnings results for BioAge Labs Inc.Navigate the market with precision tools - Jammu Links News
BioAge Labs Requests to Dismiss Class Action Filed by Investors - TradingView
BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery - MSN
Published on: 2025-07-29 06:11:56 - beatles.ru
Price Channel Expanding on BioAge Labs Inc.’s ChartAccurate Buy Point for Momentum Stocks Detected - beatles.ru
BioAge to Analyze Over 17,000 Biobank Samples for Drug Discovery - AInvest
How to interpret RSI for BioAge Labs Inc. stockFree Trade Ready Stock Watch for Short Term - Newser
Published on: 2025-07-29 09:16:13 - metal.it
Can BioAge Labs Inc. Bounce Back From Weekly LowWeekly Top Gainers Forecast Watchlist Released - metal.it
Will BioAge Labs Inc. Benefit From Sector TailwindsReal Time Stock Movement Analysis Indicates Breakout - metal.it
Competitive Positioning of BioAge Labs Inc.: Is It Leading or LaggingLow Risk Entry Points - metal.it
How strong is BioAge Labs Inc. company’s balance sheetInvest confidently with data-backed picks - Jammu Links News
How BioAge Labs Inc. stock performs during market volatilityFree Access to Community - Newser
What analysts say about BioAge Labs Inc. stockOutstanding stock performance - Autocar Professional
Is BioAge Labs Inc. a good long term investmentOutperformance with explosive growth - PrintWeekIndia
Bioage Labs Inc (BIOA) 재무 분석
Bioage Labs Inc (BIOA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.43%
0.47%
자본화:
|
볼륨(24시간):